Nice Insight in collaboration with MILS (Machine Intelligence for Life Sciences) Group LLC launches a research and service development initiative that will focus on integration of effective low-cost AI/Machine Learning solutions into process development and control for upstream/downstream biologic drug substance manufacturing.
Many biopharmaceutical companies have successfully started using data science to advance process development and process controls. Significant increase in generation of high-quality manufacturing data and encouragement of the regulatory authorities to adopt PAT approach suggest that manufacturing data science should occupy one of the leading roles in the world of bio-manufacturing innovation.
The heterogeneity of data, complexity of feature engineering and effective model development and deployment require a significant investment into dedicated data science organizations, thus preventing some biopharmaceutical companies from achieving the full potential of biomanufacturing innovation.
To automate the process development, scale up experimentation, and adopt the real-time process control and optimization, a transition towards AI/Machine Learning tools might be required.
Nice Insight and MILS Group invite biopharmaceutical companies to join the initiative and discover cost saving and quality improving potential of AI/ML solutions in biomanufacturing process development and control.
+1 212 366 4455